🔴 NMRA is trading 8.2% down today as selling persists after drug failures and restructuring

NMRA is trading 8.2% down at $1.48 as investors continue to sell following the company’s late-stage depression drug failures and restructuring moves.

• The stock remains under pressure after navacaprant failed multiple Phase III trials for Major Depressive Disorder (MDD), leading to the discontinuation of the program.
• Neumora is currently implementing a roughly 35% workforce reduction and faces an ongoing shareholder investigation following the clinical setbacks.
• Today’s decline appears to be a continuation of negative sentiment and investor repositioning as the company navigates its recent failures.